Learn About Fibrosarcoma

What is the definition of Fibrosarcoma?
A fibroblastic sarcoma is a malignant tumor derived from fibrous connective tissue and characterized by immature proliferating fibroblasts or undifferentiated anaplastic spindle cells.
What are the alternative names for Fibrosarcoma?
  • Fibrosarcoma
Who are the top Fibrosarcoma Local Doctors?
Mark A. Dickson
Elite in Fibrosarcoma
Hematology Oncology | Hematology | Oncology
Elite in Fibrosarcoma
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

Elite in Fibrosarcoma
Hematology Oncology | Hematology | Oncology
Elite in Fibrosarcoma
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

 
 
 
 
Learn about our expert tiers
Learn More
Christian F. Meyer
Elite in Fibrosarcoma
Elite in Fibrosarcoma

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, Fibrosarcoma, Osteosarcoma, and Salpingo-Oophorectomy.

What are the latest Fibrosarcoma Clinical Trials?
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Summary: This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors

Summary: This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Fibrosarcoma?